Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Breast Cancer

Breast Cancer The current attractiveness of preoperative chemotherapy for breast cancer lies in its ability to down-stage both the primary tumor and the axillary lymph nodes, making many patients good candidates for breast-conserving surgical techniques. This has been an important achievement, particularly for patients considered to have inoperable tumors. Attention has recently turned to the use of preoperative chemotherapy for patients with operable tumors. Among patients with resectable stage II or III breast tumors, preoperative chemotherapy has been demonstrated to effectively down-stage the primary tumor, and subsequent breastconserving surgery has resulted in excellent local control. In addition, preoperative chemotherapy has been shown to down-stage axillary lymph nodes from positive to negative in significant numbers of cases. This finding raises the question of whether patients who have clinically negative axillae after preoperative chemotherapy need to risk the morbidity associated with axillary lymph node dissection. Axillary irradiation may provide adequate regional control in patients who are clinically node-negative. In addition, sentinel lymph node dissection has been shown to provide accurate assessment of the axilla in patients who have received preoperative chemotherapy. Future directions with the concept of preoperative chemotherapy focus on the possibility that primary tumor ablation that takes place after the completion of systemic therapy can become minimally invasive, and thus can be done in an outpatient setting without the need for an operating room suite. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Breast Cancer

Singletary, S.
American Journal of Cancer , Volume 1 (2) – Aug 9, 2012
Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/breast-cancer-It0hygxZrg
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201020-00005
Publisher site
See Article on Publisher Site

Abstract

The current attractiveness of preoperative chemotherapy for breast cancer lies in its ability to down-stage both the primary tumor and the axillary lymph nodes, making many patients good candidates for breast-conserving surgical techniques. This has been an important achievement, particularly for patients considered to have inoperable tumors. Attention has recently turned to the use of preoperative chemotherapy for patients with operable tumors. Among patients with resectable stage II or III breast tumors, preoperative chemotherapy has been demonstrated to effectively down-stage the primary tumor, and subsequent breastconserving surgery has resulted in excellent local control. In addition, preoperative chemotherapy has been shown to down-stage axillary lymph nodes from positive to negative in significant numbers of cases. This finding raises the question of whether patients who have clinically negative axillae after preoperative chemotherapy need to risk the morbidity associated with axillary lymph node dissection. Axillary irradiation may provide adequate regional control in patients who are clinically node-negative. In addition, sentinel lymph node dissection has been shown to provide accurate assessment of the axilla in patients who have received preoperative chemotherapy. Future directions with the concept of preoperative chemotherapy focus on the possibility that primary tumor ablation that takes place after the completion of systemic therapy can become minimally invasive, and thus can be done in an outpatient setting without the need for an operating room suite.

Journal

American Journal of Cancer – Springer Journals

Published: Aug 9, 2012

References

  • Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
    Buzdar, A.U.; Singletary, S.E.; Theriault, R.L.
  • Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy
    Hortobagyi, G.N.; Ames, F.C.; Buzdar, A.U.
  • Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer
    Buzdar, A.U.; Hortobagyi, G.N.; Asmar, L.
  • Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy
    Kuerer, H.M.; Sahin, A.A.; Hunt, K.K.
  • Mastectomy following preoperative chemotherapy
    Broadwater, J.R.; Edwards, M.J.; Kuglen, C.
  • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    Kuerer, H.M.; Newman, L.A.; Smith, T.L.
  • Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T2N0M0 breast cancer
    Meric, F.; Mirza, N.Q.; Buzdar, A.U.
  • Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases
    Carter, C.L.; Allen, C.; Henson, D.E.
  • Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination
    Koscielny, S.; Tubiana, M.; Le, M.G.
  • The feasibility of minimally invasive surgery in stage IIA, IIB, and IIIA breast cancer patients after tumor downstaging with induction chemotherapy
    Vlastos, G.; Mirza, N.Q.; Lenert, J.T.
  • Feasibility of breast conservation surgery after induction chemotherapy for locally advanced carcinoma
    Singletary, S.E.; McNeese, M.D.; Hortobagyi, G.N.
  • Manual for staging of cancer
  • Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
    Bonadonna, G.; Veronesi, U.; Brambilla, C.
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer
    Jacquillat, C.; Weil, M.; Baillet, F.
  • Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumor considered too large for breast conserving surgery: preliminary results of a randomized trial: S6
    Scholl, S.M.; Fourquet, A.; Asselain, B.
  • Conservation surgery after primary chemotherapy in large carcinomas of the breast
    Veronesi, U.; Bonadonna, G.; Zurrida, S.
  • Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
    Powles, T.J.; Hickesh, T.F.; Makris, A.
  • Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    Fisher, B.; Bryant, J.; Wolmark, N.
  • Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute
    Bonadonna, G.; Valagussa, P.; Brambilla, C.
  • A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer
    Makris, A.; Powles, T.J.; Ashley, S.E.
  • Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe sein (IBBGS)
    Mauriac, L.; MacGrogan, G.; Avril, A.
  • American Society Clinical Oncology educational book
    Singletary, S.E.; Kuerer, H.M.
  • Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients
    Lenert, J.T.; Vlastos, G.; Mirza, N.Q.
  • Systemic treatment after sentinel lymph node biopsy in breast cancer: who, what and why?
    Singletary, S.E.
  • Sentinel lymph node biopsy is accurate following neoadjuvant chemotherapy for breast cancer
    Breslin, T.M.; Cohen, L.; Sahin, A.
  • Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?
    Haid, A.; Tausch, C.; Lang, A.
  • Primary systemic therapy in operable breast cancer
    Wolff, A.C.; Davidson, N.E.
  • Detection with MR imaging of residual tumor in the breast soon after surgery
    Soderstrom, C.E.; Harms, S.E.; Farrell, R.S.
  • Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging
    Abraham, D.C.; Jones, R.C.; Jones, S.E.
  • Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging
    Esserman, L.; Hylton, N.; Yassa, L.
  • Positron emission tomography using [(18) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
    Schelling, M.; Avril, N.; Nahrig, J.
  • Locally advance breast carcinoma: computer assisted semiquantitative analysis of color Doppler ultrasonography in the evaluation of tumor response to neoadjuvant chemotherapy
    Huber, S.; Medl, M.; Helbich, T.
  • Radiofrequency ablation of solid tumors
    Mirza, A.N.; Fornage, B.D.; Sneige, N.
  • Radiofrequency ablation of breast cancer: first report of an emerging technology
    Jeffrey, S.S.; Birdwell, R.L.; Ikeda, D.M.
  • Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 16 patients
    Izzo, F.; Thomas, R.
  • Sequencing therapeutic interventions in early and advanced primary breast cancer
    Singletary, S.E.